EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Skin sign outcomes with upadacitinib vs dupilumab in moderate-to-severe atopic dermatitis: a post hoc analysis of the level up study

Jordan Talia, Walter Liszewski, Masatoshi Abe, Li Chao, Kaili Ding, Tanjinatus Oishi, Alvaro Moreira, Brian Calimlim, Juan Francisco Silvestre

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s844

DOI: 10.25251/cvr9s032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Jordan Talia und 8 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Atopic dermatitis (AD) is a chronic, relapsing inflammatory disease characterized by eczematous lesions and intense itch. The Eczema Area and Severity Index (EASI) assesses the severity of 4 clinical signs — erythema, edema, excoriation, and lichenification — however, treatment response based on the total EASI score can obscure how individual signs respond. In the phase 3b/4 Level Up study (NCT05601882), upadacitinib (UPA) was superior to dupilumab (DUPI) in achieving both high skin clearance (EASI 90) and little-to-no itch in adolescents and adults with moderate-to-severe AD. Given their distinct mechanisms of action with UPA, a JAK1 inhibitor, and DUPI, an IL-4/IL-13 inhibitor, it remains unclear whether UPA’s superiority extends across the individual signs, particularly harder-to-treat signs such as lichenification and excoriation. This post hoc analysis of Level Up assessed improvement in each of the 4 lesion signs with UPA versus DUPI.

Methods

Patients in Level Up were randomized to UPA 15 mg (with potential dose escalation starting at week 4 for inadequate clinical response) or DUPI per label for 16 weeks. For each lesion sign, the proportions of patients achieving ≥75%/≥90%/100% EASI improvement from baseline (EASI 75/90/100) were reported over 16 weeks, with non-responder imputation for missing data. Nominal P values for between-group differences were based on Cochran-Mantel-Haenszel tests stratified by baseline vIGA-AD category and age group.

Results

A total of 458 patients were randomized to UPA and 462 to DUPI. Across all 4 lesion signs, greater proportions of patients receiving UPA than DUPI achieved sign-specific EASI 75/90/100, with treatment differences evident as early as week 2. At week 2, EASI 75/90/100 response rates for erythema were 23.6% vs 6.3%, 6.8% vs 1.5%, and 2.6% vs 0.7% for UPA vs DUPI, respectively. Similar trends were observed for edema (EASI 75 [26.0% vs 12.4%], EASI 90 [11.9% vs 5.2%], EASI 100 [7.5% vs 3.9%]), excoriation (EASI 75 [37.4% vs 17.6%], EASI 90 [21.0% vs 8.9%], EASI 100 [12.3% vs 6.3%]), and lichenification (EASI 75 [22.5% vs 9.6%], EASI 90 [9.4% vs 2.8%], EASI 100 [6.1% vs 2.2%]). Treatment differences were maintained through week 16. At week 16, sign-specific EASI 75/90/100 response rates for UPA vs DUPI were as follows: erythema – 54.1% vs 34.5%, 36.0% vs 19.5%, 17.9% vs 7.4%; edema – 60.4% vs 40.0%, 43.6% vs 27.4%, 26.0% vs 18.7%; excoriation – 62.6% vs 44.0%, 48.4% vs 33.1%, 35.0% vs 23.7%; and lichenification – 56.9% vs 38.6%, 40.7% vs 23.5%, 24.9% vs 13.7%. All comparisons across all time points evaluated were nominally significant (P < .05).

Conclusion

Treatment of moderate-to-severe AD with UPA resulted in a greater proportion of patients achieving EASI 75/90/100 in the 4 AD lesion signs of erythema, edema/papulation, excoriation, and lichenification compared with DUPI. Improvements were observed as early as week 2 and sustained through week 16. Sign-level differences may help clinicians individualize therapy and counsel patients on expected improvement trajectories, particularly for chronic, harder-to-treat signs such as lichenification and excoriation.

Zitieren

APA

Talia, J., Liszewski, W., Abe, M., Chao, L., Ding, K., Oishi, T., Moreira, A., Calimlim, B., & Silvestre, J. F. (2026). Skin sign outcomes with upadacitinib vs dupilumab in moderate-to-severe atopic dermatitis: a post hoc analysis of the level up study. SKIN The Journal of Cutaneous Medicine, 10(6), s844. https://doi.org/10.25251/cvr9s032

Vancouver

Talia J, Liszewski W, Abe M, Chao L, Ding K, Oishi T, et al. Skin sign outcomes with upadacitinib vs dupilumab in moderate-to-severe atopic dermatitis: a post hoc analysis of the level up study. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s844. doi:10.25251/cvr9s032

BibTeX
@article{Talia2026,
  author = {Talia, Jordan and Liszewski, Walter and Abe, Masatoshi and Chao, Li and Ding, Kaili and Oishi, Tanjinatus and Moreira, Alvaro and Calimlim, Brian and Silvestre, Juan Francisco},
  title = {Skin sign outcomes with upadacitinib vs dupilumab in moderate-to-severe atopic dermatitis: a post hoc analysis of the level up study},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s844},
  doi = {10.25251/cvr9s032}
}
Kostenlos starten →